Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Nutex Health, Inc. (NUTX)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$193.64-5.64%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
27.87 → 27.32 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NUTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve EPS of at least $21.52 in FY 2026 and $23.03 in FY 2027 | A primary condition in Nutex Health, Inc.'s published investment case. The stated target is >= $21.52 (2026), >= $23.03 (2027). | Broken | EPS falls below $15 in FY 2026 or below $18 in FY 2027 | Diluted EPS: $9.38 per share FY2026-Q2; GAAP. Published target: >= $21.52 (2026), >= $23.03 (2027). Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 20269.38 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
NUTX is a high-risk growth business with a healthcare sector tailwind, rather than a steady, low-risk compounder. Its long-term thesis is intact: recent performance remains strong, and hospital expansion is on track.
The valuation evidence is mixed: NUTX is described as cheap versus peers, while the model also shows a 0.36 premium versus peers. The priced-in tag is justified, with no fragility gates triggered, but the expectations gap is negative and its meaning is uncertain at medium confidence.
Near term, the next call and any guidance changes matter, as recent earnings surprises have been erratic and are trending down. For the multi-year view, three planned hospital openings in 2026, higher patient visits, and first-half operating income growth support the business trajectory, though the profitability priority is marked mixed.
The thesis depends on management continuing hospital expansion and sustaining operating improvements. A guidance cut or further weakening in jobs data would raise concerns, while continued earnings strength and higher guidance from sector bellwethers would support the healthcare backdrop.
Over the next 1 to 3 years, NUTX has evidence of real operating progress, but its high risk and potential sensitivity to guidance and economic weakness make the thesis conditional. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Increase operating income to at least $81.3M in 2026-Q1 | Nutex Health is growing profitably with operating income rising from $30.9M to $81.3M in one quarter. | Broken | operating income falls below $30 million in any quarter after 2026-Q1 | Operating income: $121.718M FY2026-Q2; GAAP. Published target: >= $81.3 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026121,718,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue growth near 7% annually | A supporting condition in Nutex Health, Inc.'s published investment case. The stated target is >= 6.7% YoY. | Improving | revenue growth falls below 5% YoY | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain valuation discount with PE below 15 | A supporting condition in Nutex Health, Inc.'s published investment case. The stated target is <= 15 PE. | Intact | PE rises above 20 without earnings growth | P/E (TTM): 8.31x As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 20268.3085 ratio · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$23.03 → $27.32 · observed estimates
$0.97B → $0.96B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-25 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-26 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-27 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-28 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-29 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-30 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-07-31 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-01 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-02 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-03 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-04 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-05 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-06 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-07 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-08 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-09 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-10 | $23.03 | $969,209,200 | 5 / 5 |
| 2026-08-12 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-13 | $27.80 | $964,929,200 | 5 / 5 |
| 2026-08-14 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-15 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-16 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-17 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-18 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-19 | $23.03 | $969,209,200 | 3 / 3 |
| 2026-08-20 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-21 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-22 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-23 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-24 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-25 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-26 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-27 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-28 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-29 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-30 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-08-31 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-09-01 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-09-02 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-09-03 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-09-04 | $28.83 | $965,320,270 | 3 / 3 |
| 2026-09-05 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-06 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-07 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-08 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-09 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-10 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-11 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-12 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-13 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-14 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-15 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-16 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-17 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-18 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-19 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-20 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-21 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-22 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-23 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-24 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-25 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-26 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-27 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-28 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-29 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-09-30 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-01 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-02 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-03 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-04 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-05 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-06 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-07 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-08 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-09 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-10 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-11 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-12 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-13 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-14 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-15 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-16 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-17 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-18 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-19 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-20 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-21 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-22 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-23 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-24 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-25 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-26 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-27 | $27.87 | $964,200,270 | 3 / 3 |
| 2026-10-28 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-10-29 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-10-30 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-10-31 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-11-01 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-11-02 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-11-03 | $27.32 | $959,748,325 | 4 / 4 |
| 2026-11-04 | $27.32 | $959,748,325 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.